Are the Concerns of Investor Hushed? Alnylam Achieves RNAi Milestone | Medindia
Alnylam Pharmaceuticals has received a $3.2m milestone payment from GSK as part of their ongoing collaboration to use Alnylam’s RNAi technology to develop GSK’s cell-culture based influenza vaccine.
http://www.medindia.net/news/are-the-concerns-of-investor-hushed-alnylam-achieves-rnai-milestone-104961-1.htm
Alnylam Pharmaceuticals has received a $3.2m milestone payment from GSK as part of their ongoing collaboration to use Alnylam’s RNAi technology to develop GSK’s cell-culture based influenza vaccine.
http://www.medindia.net/news/are-the-concerns-of-investor-hushed-alnylam-achieves-rnai-milestone-104961-1.htm
No comments:
Post a Comment